The source title reports a single-centre case series published in Frontiers in Immunology describing confirmed and suspected heparin-induced thrombocytopenia (HIT) occurring during therapeutic plasma exchange (TPE) in patients with neuromyelitis optica spectrum disorder (NMOSD). The title identifies the clinical context (NMOSD), the intervention (TPE), and the complication of interest (confirmed and suspected HIT) and specifies that the report is from a single centre and presented as a case series.
The excerpt of the source provided for this rewrite contains website navigation, journal sections, and metadata from Frontiers in Immunology but does not include the article body. As a result, the following critical components of the article were not available in the supplied material and therefore cannot be summarized here: explicit case descriptions, number of patients, timelines, diagnostic test results, procedural and anticoagulation details, management steps, complications, outcomes, and the authors’ discussion or conclusions.
Because the supplied content lacks the main manuscript text, no additional facts, numerical data, or inferred outcomes are included in this summary. Any clinical details beyond those explicitly named in the article title were not reported in the source excerpt and are not presented here.
The manuscript is a case report / single-centre case series.
The clinical scenario involves therapeutic plasma exchange (TPE) administered to patients with neuromyelitis optica spectrum disorder (NMOSD).
The complication of interest is both confirmed and suspected heparin-induced thrombocytopenia (HIT) occurring during TPE.
The article was published in the journal Frontiers in Immunology (as indicated by site metadata in the provided excerpt).
No further specific clinical, diagnostic, or outcome information was present in the provided source content.
The supplied source excerpt did not include the manuscript text, so the following important clinical and methodological details were not reported and cannot be summarized here:
Number of cases in the case series and how many were classified as confirmed versus suspected HIT.
Patient demographics, comorbidities, baseline platelet counts, and NMOSD treatment indications prompting TPE.
TPE procedural details such as vascular access type, use of heparin for catheter patency or systemic anticoagulation, replacement fluid selection, and session frequency.
Timing of platelet count changes relative to heparin exposure and TPE sessions (onset days, nadir values).
Laboratory testing used to support HIT diagnosis (anti-PF4/heparin immunoassays, optical density values, functional platelet activation assays) and interpretation of results.
Management strategies after HIT was suspected or confirmed (cessation of heparin, alternative anticoagulants used, changes to TPE protocol) and rationale.
Presence or absence of thrombotic or bleeding complications and short- and long-term patient outcomes.
Authors’ recommendations, limitations, and suggested changes to clinical practice or procedural protocols.
Because these items were not present in the source excerpt, they are explicitly omitted from this summary rather than being inferred.
Based solely on the article title and metadata available in the provided source excerpt, clinicians should note that the authors reported at least one instance of confirmed or suspected HIT during TPE in patients with NMOSD at a single centre. However, without access to the full manuscript, clinicians cannot evaluate the strength of the evidence, the diagnostic approach, or the appropriateness of management decisions described by the authors.
For clinicians considering practice implications—such as anticoagulation strategies during TPE, monitoring platelet counts, diagnostic testing for HIT, or alternative anticoagulants—review of the full article is necessary to assess applicability and to extract practical details.
The complete article appears in Frontiers in Immunology. The full manuscript, supplementary materials, and author disclosures should be consulted to obtain patient-level data, diagnostic criteria, laboratory results, procedural details, and authors’ conclusions. The supplied excerpt did not contain a usable article body; therefore, readers should access the journal web page or institutional resources to retrieve and read the original publication before applying any clinical changes.
Note: This rewritten summary preserves only the facts explicitly present in the provided source excerpt. Specific numerical data, case details, diagnostic thresholds, and management decisions were not available in the excerpt and are not reported here.